Good Phase III results for Regeneron and Sanofi’s Dupixent

Regeneron Pharmaceuticals and Sanofi have announced at the  27th European Academy of Dermatology and Venereology (EADV) Congress, in Paris, positive results from a Phase III clinical trial assessing Dupixent (dupilumab) on adolescents with atopic dermatitis.

The study was conducted on 251 patients aged 12 to 17 years old: those treated with Dupixent as monotherapy reported significant improvement in symptoms, and therefore in quality of life. Importantly, Dupixent has already been approved in the US and Europe for some indications; this is the first clinical trial on adolescents.

(Sources: Sanofi, Regeneron)